Federal Court to EPA: No, You Can’t Approve This Pesticide That Kills Bees

<a href="http://www.shutterstock.com/pic-110485346/stock-photo-honey-bee-on-yellow-flower-close-up-macro.html?src=yr8wU17TXxbJAaNSKqJSlQ-1-1">Dancestrokes</a>/Shutterstock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


On Thursday, a federal appeals court struck down the Environmental Protection Agency’s approval of a pesticide called sulfoxaflor. Marketed by agrichemical giant Dow AgroSciences, sulfoxaflor belongs to a class of pesticides called neonicotinoids, which have been implicated by a growing weight of evidence in the global crisis in bee health. In a blunt opinion, the court cited the “precariousness of bee populations” and “flawed and limited data” submitted by Dow on the pesticide’s effects on beleaguered pollinating insects.

“I am inclined to believe the EPA…decided to register sulfoxaflor unconditionally in response to public pressure for the product and attempted to support its decision retroactively with studies it had previously found inadequate,” said a circuit judge.

Before winning approval for sulfoxaflor back in 2013, the company hyped the product to investors, declaring that it “addresses [a] $2 billion market need currently unmet by biotech solutions,” particularly for cotton and rice.

US beekeepers were less enthusiastic—a group of national beekeeping organizations, along with the National Honey Bee Advisory Board, quickly sued the EPA to withdraw its registration of sulfoxaflor, claiming that the EPA itself had found sulfoxaflor to be “highly toxic to honey bees, and other insect pollinators.”

Thursday’s ruling, a response to that suit, took their side. It applies only to sulfoxaflor, which Dow markets as a foliar spray on a variety of crops, including cotton, soybean, citrus, stone fruit, nuts, grapes, potatoes, vegetables, and strawberries. It has no bearing on the EPA’s equally controversial approval of other neonics like clothianidin  and imidacloprid, which are widely used as seed treatments on the two most prominent US crops: corn and soybeans.

But Greg Loarie, an attorney for EarthJustice who argued the case for the beekeeper’s coalition, told me that the decision has broad significance because the ruling “makes clear” that when the EPA is assessing new pesticides, it must assess robust data on the health impacts on the entire hive, not just on individual adult bees.

In its opinion, the court rebuked the EPA for approving sulfoxaflor despite “inconclusive or insufficient data on the effects…on brood development and long-term colony health.” That’s a problem, the court added, because pesticides can cause subtle harm to bees that don’t kill them but that “ripple through the hive,” which is an “interdependent ‘superorganism.'” Indeed, many independent studies have demonstrated just such effects—that low-level exposure to neonics is “sub-lethal” to individual bees but compromises long-term hive health.

“The EPA doesn’t have that [hive-level] information on very many insecticides, if any,” Loarie said.

And in the case of sulfoxaflor, the agency didn’t try very hard to get that information. In January 2013, because of major gaps in research on the new chemical’s effect on bees, the EPA decided to grant sulfoxaflor “conditional registration” and ordered Dow to provide more research. And then a few months later, the agency granted sulfoxaflor unconditional  registration—even though “the record reveals that Dow never completed the requested additional studies,” the court opinion states.

In an even more scathing addendum to the court’s main opinion, Circuit Judge N.R. Smith added, “I am inclined to believe the EPA…decided to register sulfoxaflor unconditionally in response to public pressure for the product and attempted to support its decision retroactively with studies it had previously found inadequate.” The judge added, “Such action seems capricious.”

Sulfoxaflor’s twisted path through the EPA’s approval process isn’t the first time the agency has green-lighted a neonicotinoid pesticide under dodgy circumstances, as I showed in this 2010 piece on clothianidin, a widely marketed pesticide marketed by Dow’s European rival, Bayer.

In 2013—the same year the EPA approved sulfoxaflor—the European Union placed a two-year moratorium on clothianidin and two other major neonics, citing pollinator health concerns. For a study released last year, the US Geological Survey found neonic traces in all the Midwestern rivers and streams it tested, declaring them to be “both mobile and persistent in the environment.” In addition to harming bees, neonics may also harm birds and fish, Canadian researchers have found.

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate